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Abstract
Background: The presence of psoriasis is currently considered by the European Society of Cardiology 
cardiovascular prevention guidelines of 2016 as one possible cardiovascular risk factor. Patients with 
psoriasis and concomitant coronary artery disease treated by means of percutaneous coronary interven-
tion (PCI) are a fairly large subgroup of patients that have been usually omitted in mainstream research. 
The aim herein, was to identify the incidence of psoriasis, baseline characteristics and periprocedural 
outcome with a special focus on procedural complications in patients undergoing percutaneous coronary 
procedures. 
Methods: All consecutive patients who had either coronary angiography or coronary angiography 
with immediate PCI in Poland in 2014 and 2015 were included. Patients were assigned to two groups 
based on previous diagnosis: with psoriasis and without psoriasis. Clinical outcome was defined as any 
periprocedural death. 
Results: There were 405,078 patients included in this analysis. Psoriasis (moderate or severe) was di-
agnosed in 1507 (0.4%) of them. Psoriasis was an independent predictor of allergic reaction occurrence 
(odds ratio [OR] 6.02; 95% confidence interval [CI] 1.44–25.22; p = 0.014). After propensity score 
adjustment, psoriasis remained a significant predictor of allergic reaction (OR 5, 95% CI 1.2–20.7; 
p = 0.0245). There were no differences in rates of periprocedural deaths in patients with or without 
psoriasis (death: 0.95% vs. 0.62%, p > 0.05).
Conclusions: Severe or moderate psoriasis is an independent risk factor for the occurrence of allergic 
reaction during percutaneous coronary procedures. There were no differences in periprocedural mortal-
ity and complications in patients with versus those without psoriasis. (Cardiol J 2020; 27, 3: 278–284)
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Introduction
Psoriasis is a chronic autoimmune inflamma-
tory disease, the prevalence of which  ranges from 
1.5% to 4.7% in the general population making it 
a significant healthcare issue [1–3]. The immune-
mediated inflammatory pathogenesis of psoriasis 
is linked to another inflammatory disease which is 
atherosclerosis [4, 5]. The presence of psoriasis 
is currently considered by the European Society 
of Cardiology (ESC) cardiovascular prevention 
guidelines of 2016 as one possible cardiovascular 
risk factors within a wide group of autoimmune and 
inflammatory diseases [6]. Currently the American 
Heart Association (AHA) recommendations include 
risk factor screening in patients with psoriasis 
from as early as age 20 and by the age 40 a full 
list of these including various cardio-metabolic 
parameters need to be identified [7, 8]. Retro-
spective data concerning the effect of psoriasis on 
cardiovascular morbidity and mortality seem to 
confirm its adverse outcome on the occurrence of 
myocardial infarction or development of coronary 
artery disease, however, meta-analysis and litera-
ture reviews provide inconclusive data, probably 
because of confounding factors and the moderate 
quality of cardiovascular risk factor reporting (pso-
riasis) in large datasets [9–13]. In the Rotterdam 
study, authors did not find a correlation between 
mild psoriasis and risk for the development of car-
diovascular events or atherosclerosis which seems 
to support the general consensus that if any, pso-
riasis may have its deleterious effect only if at least 
moderate or severe presentation is expressed [14]. 
A combined clinical endpoint of death, myocardial 
infarction and stroke was more frequent in patients 
with severe psoriasis than in those without, which 
is the only prospective observation available thus 
far [15, 16].
Patients with psoriasis and concomitant coro-
nary artery disease treated by means of percutane-
ous coronary intervention (PCI) are a fairly large 
(in definite numbers) subgroup of patients that 
have usually been omitted in mainstream research. 
The main aim of this analysis was to identify 
the incidence of psoriasis, baseline characteristics 
and periprocedural outcome with a special focus 
on procedural complications in this subgroup of 
patients.
Methods
The Polish National PCI database (ORPKI) 
is a registry (with eCRF) for all percutaneous 
coronary procedures that have been performed in 
Poland since 2004 and is currently operated by the 
Jagiellonian University Medical College in Krakow. 
Annual reports are published each year and the 
registry rationale has been described before [17, 
18]. In this manuscript, data for the calendar year 
2014 (January–December) and 2015 (January–De-
cember) were analyzed. All consecutive patients 
who had either coronary angiography or coronary 
angiography with immediate PCI in 155 interven-
tional cardiology centers in Poland were included 
in this analysis. Patients with incomplete records 
concerning baseline characteristics were excluded. 
The reason for analyzing data from 2014 onwards 
was due to the fact that psoriasis was implemented 
for the first time into eCRF of the ORPKI database 
on January 1st, 2014.
Periprocedural mortality was defined as death 
from any cause during angiography/PCI. Psoriasis 
was defined as severe or moderate presentation 
as confirmed by prior diagnosis by a dermatologist 
(PASI index > 10). Only moderate and severe pres-
entations were taken into account since they have 
been proven to have an impact on cardiovascular 
disease [6, 11, 13]. Allergic reaction was defined as 
any hypersensitive response of the immune system 
presenting as: bronchospasm, asthma exacerba-
tion, conjunctivitis, urticaria, eczema, angioedema, 
anaphylactic shock. All these symptoms had to be 
revealed during a patient stay at a catheteriza-
tion laboratory and had not been present prior to 
admission.   
Other complications or adverse events were 
diagnosed at the operator’s discretion according 
to current ESC definitions. Clinical outcome was 
defined as any periprocedural death. No further 
evaluation or follow-up of patients was performed. 
All patients provided informed consent. The study 
complied with ethical principles for clinical re-
search based on the Declaration of Helsinki with 
later amendments. No external funding was used 
to support this registry.
Statistical analysis
Categorical variables were presented as num-
bers and percentages. The distributions of continu-
ous variables were expressed as mean ± standard 
deviation (SD), standard error (SE), median with 
interquartile range (IQR). Additionally, the number 
of available cases and minimum and maximum 
values were also presented. Normality was as-
sessed by the Lilliefor test. Equality of variances 
were assessed using the Levene test. Differences 
between groups were compared using the Stu-
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dent or Welch t-test depending on the equality of 
variances for normally distributed variables. The 
Mann-Whitney U test was used for non-normally 
distributed continuous variables. Categorical vari-
ables were compared with the Fisher exact test for 
the 2 × 2 tables or by the Pearson c2 test for the 
other tables. P-values less than 0.05 were assumed 
to indicate statistical significance. 
Simple logistic regression was used for each 
of potential factor as a predictor for occurrence of 
allergic reaction. Then if p-value for a specific factor 
was less than 0.2 such factor was introduced into 
multiple logistic regression. The recommendation 
for using a significance level as high as 0.20 or 0.25 
as screening criterion for initial variable selection 
is based on work by Bendel and Afifi (1977) [19] 
on linear regression and on work by Mickey and 
Greenland (1989) [20] on logistic regression. Only 
significant predictors and potential confounders (for 
adjustment) remained in the final model. The same 
procedure was repeated considering correction 
for rare events [21]. Both models were diagnosed 
using receiver operating characteristic curve and 
area under curve parameter. 
The propensity score for psoriasis was calcu-
lated based on diabetes, hypertension, smoking, 
clinical diagnosis, kidney disease, presence of mul-
tivessel disease glycoprotein inhibitor use, access 
site, contrast volume, radiation, age, weight and 
gender. Then the odds for allergic reaction were 
calculated using logistic regression with presence 
of psoriasis as a covariate and was conditioned on 
propensity score. 
Analysis was performed in JMP® 9.0.0. (SAS 
Institute Inc., Cary, NC, 1989–2007) and R 3.3.0. 
(A language and environment for statistical com-
puting. R Foundation for Statistical Computing, 
Vienna, Austria).
Results
There were 405,078 patients with full records 
in the ORPKI database for the period of January 
1st 2014 till December 31st 2015 were included in 
this analysis. Psoriasis (moderate or severe) was 
diagnosed in 1507 (0.4%) of them. Patient baseline 
and clinical characteristics are presented in Table 1. 
Procedural outcome as well as frequency of com-
plications in patients with and without psoriasis are 
presented in Table 2. The occurrence of peripro-
cedural death, stroke and sudden cardiac arrest 
did not differ between the groups even though 
baseline and clinical characteristics in patients 
with psoriasis were high risk (significantly higher 
prevalence of diabetes, prior myocardial infarction, 
smoking and hypertension). Allergic reaction was 
more frequent during PCI in patients with psoriasis 
than in those without psoriasis (0.08% vs. 0.41%, 
p = 0.0226). There was no differences in the oc-
currence of periprocedural complications and death 
between the studied groups. Independent predic-
tors of allergic reaction occurrence are presented 
in Table 3. Psoriasis was an independent predictor 
of allergic reaction occurrence (odds ratio [OR] 
6.02; 95% confidence interval [CI] 1.44–25.22; 
p = 0.014). After propensity score adjustment 
psoriasis remained a significant predictor of aller-
gic reaction (OR 5; 95% CI 1.2–20.7, p = 0.0245). 
Model adjustment for logistic regression is pre-
sented in Figure 1.
Discussion
Since psoriasis usually presents for the first 
time in adolescents and young adults, it is a lifelong 
burden and has a possible impact for development 
of other comorbidities. Psoriatic arthritis may ap-
pear in up to 30% of patients leading to decreased 
mobility and thus permanent disability which is 
an adverse condition for primary prevention of 
cardiovascular disease, metabolic syndrome and 
insulin resistance in diabetes mellitus [12]. The 
present study has confirmed more aggravating 
past medical history, comorbidities and higher risk 
demographics for patients with diagnosed psoriasis 
who were scheduled for coronary angiography and 
or PCI, either elective or urgent one. Mild psoriasis 
accounts for approx. 60% of all cases. The overall 
frequency of psoriasis (0.4%) was lower than in pre-
vious studies, however, the present focus was only 
on severe and moderate forms of psoriasis which 
have been documented to impact cardiovascular 
morbidity [11, 16, 22]. 
Recent coronary computed tomography stud-
ies revealed that patients with psoriasis had 
greater plaque burden and high risk plaque preva-
lence which was reduced at 1 year of observation 
following effective anti-inflammatory treatment 
which was revealing for the first time that such 
a correlation was observed [23]. Severe forms of 
psoriasis have also been named as a strong and 
independent predictor of ischemic stroke [24]. 
As previously observed, it seems that if any, 
psoriasis may have its deleterious effect only if 
it was at least expressed as moderate or severe 
presentation and this is the group which was 
under investigation herein. Even though patients 
with psoriasis in the registry were higher risk in-
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Table 2. Clinical outcome and procedural complications.
Variable No psoriasis
N = 182,244 (PCI)
N = 221,327  
(Angiography)
Psoriasis
N = 740 (PCI)
N = 767  
(Angiography)
P
Death during angiography 172 (0.08%) 0 (0%) 1.000
Death during PCI 983 (0.54%) 7 (0.95%) 0.128
SCA during angiography 905 (0.22%) 7 (0.46%) 0.0901
SCA during PCI 884 (0.49%) 6 (0.81%) 0.1818
Allergic reaction during angiography 160 (0.07%) 0 (0%) 1.000
Allergic reaction during PCI 145 (0.08%) 3 (0.41%) 0.0226
Stroke during angiography or PCI 55 (0.01%) 0 (0%) 1.000
Coronary artery perforation during PCI 295 (0.16%) 0 (0%) 0.6373
MI during PCI 173 (0.09%) 0 (0%) 1.000
No-reflow during PCI 1062 (0.58%) 8 (1.08%) 0.0850
MI — myocardial infarction; PCI — percutaneous coronary intervention; SCA — sudden cardiac arrest
Table 1. Baseline demographic, clinical characteristic and procedure.
Variable No psoriasis  
N = 403,571
Psoriasis  
N = 1507
P
Male gender 250,127 (62%) 1041 (69.1%) < 0.0001
Age 66.3 ± 10.9 63.3 ± 10.6 < 0.0001
Diabetes 90,043 (22.3%) 492 (32.7%) < 0.0001
Prior MI 91,235 (22.6%) 383 (25.4%) 0.01
Prior PCI 102,131 (25.3%) 389 (25.8%) 0.656
Prior CABG 23,406 (5.8%) 81 (5.4%) 0.508
Smoking — active 68,486 (17%) 427 (28.3%) < 0.0001
Hypertension 284,271 (70.4%) 1129 (74.9%) 0.0001
Indication: 0.0002
STEMI 48317 (11.9%) 219 (14.5%)
NSTEMI 52864 (13.1%) 240 (15.9%)
Unstable angina 124,322 (30.8%) 440 (29.2%)
Stable angina 158,635 (39.3%) 542 (35.9%)
Angiography only 221,327 (54.8%) 767 (50.9%) 0.0022
Multivessel disease with or without LMCA involvement 151,538 (37.7%) 643 (42.8%) < 0.0001
P2Y12 during the procedure 88,757 (21.9%) 397 (26.3%) 0.0002
UFH during PCI 153,985 (84.5%) 644 (87%) 0.0595
LMWH during PCI 5980 (3.3%) 25 (3.4%) 0.8361
GP IIb/IIIa during PCI 12,056 (6.6%) 68 (9.2%) 0.0075
Thrombolysis during PCI 376 (0.2%) 1 (0.1%) 1.000
Contrast volume [mL] 128 ± 79 135 ± 83 < 0.0001
Radiation dose [Gy] 0.796 ± 0.952 0.957 ± 1.227 < 0.0001
CABG — coronary artery bypass grafting surgery; GP — glycoprotein; Gy — Grey; LMCA — left main coronary artery; LMWH — low molecular 
weight heparin; MI — myocardial infarction; NSTEMI — non-ST-segment elevation myocardial infarction; PCI — percutaneous coronary  
intervention; STEMI — ST-segment elevation myocardial infarction; UFH — unfractionated heparin
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dividuals with more frequent diabetes, hyperten-
sion and acute myocardial infarction (ST-segment 
elevation myocardial infarction, non-ST-segment 
elevation myocardial infarction) presentation 
as well as multivessel and more pronounced 
atherosclerosis, their immediate periprocedural 
individual outcomes like death, stroke or sudden 
cardiac arrest were similar to those without pso-
riasis (< 1%). Presently it is believed that this 
may stem from the fact that a majority of compli-
cations related to psoriasis, if any, occur at a later 
stage and may be recorded only if a longer follow 
up period is available and only in severe forms of 
psoriasis [15, 16]. Adjusting for confounders, the 
presence of psoriasis does not seem to at least 
effect the periprocedural outcome of this group 
of patients. 
The ORPKI database is one of the biggest 
datasets of consecutive patients with coronary 
artery disease treated invasively in European 
Union countries which continuously collects data 
on severe/moderate psoriasis occurrence since 
2014. No previous studies with as large numbers 
of individuals as in the present registry (> 400,000 
for a period of 2 consecutive calendar years) have 
been performed so far in investigating psoriasis as 
a comorbidity in the setting of PCIs. Big data analysis 
in this case helped identify interesting associations 
such as more frequently observed allergic reac-
tion occurrence in patients with psoriasis than in 
those without, which has remained an independ-
ent predictor even after statistical adjustments. 
It is known that several factors may contribute 
to anaphylaxis or hypersensitivity reactions dur-
ing percutaneous coronary procedures, namely 
acetylsalicylic acid, P2Y12, heparin, glycoprotein 
IIb/IIIa inhibitors and contrast use itself [25–28]. 
Stent platforms and polymers used in drug eluting 
stents may potentially induce such reactions as 
well [29, 30]. In the present study a majority of all 
these variables were taken into consideration while 
performing multivariate analysis for independent 
predictors, however, not all were available in the 
database. The results indicate that glycoprotein 
IIb/IIIa inhibitor plays a significant role in allergic 
reaction occurrence as well as radiation doses 
which are a derivative of time of the procedure. 
It is worth noting that psoriasis conferred as the 
highest adjusted risk for allergic reaction even 
after propensity score adjustment. These findings 
need further investigation and suggest that caution 
should be used for patients presenting with severe 
or moderate forms of psoriasis when referred for 
invasive diagnostic and treatment. The results of 
the study may become hypotheses generating for 
Table 3. Independent predictors of allergic reaction during angiography and/or percutaneous coronary 
intervention.
Variable OR 95% CI P
Psoriasis 6.02 1.44–25.22 0.014
Diabetes mellitus 0.47 0.24–0.92 0.026
Hypertension 0.57 0.36–0.89 0.014
STEMI/NSTEMI vs. other 0.58 0.35–0.97 0.036
GP IIb/IIIa inhibitors use 4.56 2.74–7.59 < 0.001
loge per 1 Gy (radiation dose) 1.67 1.22–2.28 0.001
Male gender 0.54 0.33–0.87 0.012
CI —  confidence interval; GP — glycoprotein; Gy — Grey; STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-ST-segment 
elevation myocardial infarction; OR — odds ratio
Figure 1. Model adjustment for logistic regression; 
AUC — area under curve.
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future clinical studies. According to available re-
search, this is the first report of such a relationship 
and requires further study. 
Limitations of the study
The main limitation of this study is the non-
randomized design. Only periprocedural outcome 
could be provided which limits the observation 
and incidence of complications that appeared in 
periods after the procedure. Statistical measures 
were undertaken to compensate for possible biases 
like propensity score matching and multivariate 
analysis in order to identify independent predic-
tors but since this is an observational study not 
all possible confounders may have been identified. 
An underreporting of psoriasis may be possible 
but only moderate or severe forms (which are less 
frequent in general population) were gathered in 
ORPKI Registry. Finally, the diagnosis of psoriasis 
(moderate or severe) was based on prior recogni-
tion by a physician and no additional data concern-
ing its treatment or systemic complications were 
gathered in this registry. 
Conclusions
Severe or moderate psoriasis is a rare co-
morbidity in patients undergoing percutaneous 
coronary procedures (< 1%). However, it is an 
independent risk factor for allergic reaction occur-
rence during percutaneous coronary procedures. 
The adjusted periprocedural mortality and compli-
cations rates were similar in those with psoriasis 
versus those without.
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